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Second, the postoperative course after standard aortic
valve replacement was uneventful, despite the important co-
morbidities of the patient that suggested PAVI. Therefore an
accurate preoperative evaluation is fundamental to identify
those patients who are not suitable for the standard surgical
procedure.
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Raffaele Bonato, MD,b Roberto Bianco, MD,c Gino Gerosa, MD,c Sabino Iliceto,a and
Angelo Ramondo, MD,a Padova, ItalyRecently, the feasibility and safety of percutaneous aortic
valve replacement (PAVR) has been reported in the treat-
ment of degenerative aortic valve stenosis in patients at
high-risk for surgical aortic valve replacement (AVR).1
However, so far this therapy has been limited to patients
with severe stenosis of the native valve. We report the
case of a patient with severe aortic regurgitation owing to
bioprosthesis dysfunction who was successfully treated by
implantation of a CoreValve (CoreValve Inc, Irvine. Calif)
prosthesis with a totally percutaneous approach.
CLINICAL SUMMARY
An 84-year-old woman, with previous surgical AVR with
a bioprosthesis (Biocor 25 mm stentless; (Biocor Industria e
Pesguisa Ltda, BeloHorizonte, Brazil) and cardiac pacemaker
implantation for severe aortic stenosis in 1998, was admitted
to a community hospital because of pulmonary edema. Co-
morbidity included hypertension, chronic renal failure, and
previous left hemicolectomy for bowelmalignancy. Transtho-
racic echocardiogram revealed a severe transprosthetic aortic
regurgitation caused by leaflet degeneration and prolapse;
the left ventricle was enlarged with moderate impairment of
systolic function. Despite medical treatment, clinical status
rapidly worsened. The case was discussed with two different
surgical teams,who deemed the patient at high risk for redoing
AVRbecause of advanced age, the risks of the redoprocedure,
and comorbidities: the logistic EuroScore was 31.8%. Thus,
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feasibility of PAVR. Cardiac catheterization and angiography
confirmed the severity of aortic regurgitation with left ven-
tricular dysfunction, increased ventricular filling pressure,
pulmonary hypertension, and decreased cardiac index. The
computed tomographic scan of the aorta and iliac and femoral
arteries showed a moderate degree of wall calcification in the
ascending aorta, with aortic root and annular dimensions ame-
nable forPAVR; the femoral and iliac arteries showeda caliber
suitable for large sheath insertion. The procedure was per-
formedwith the patient undermild sedation and local anesthe-
sia by a percutaneous retrograde approach.Over an18F sheath
percutaneously inserted in the right femoral artery, the valve
(29 mm, third-generation CoreValve Revalving system) was
introduced and retrogradely advanced under fluoroscopic
guidance over a stiff wire in the ascending aorta across the
pre-existing prosthesis plane. After careful evaluation of pros-
thesis position by angiography, the prosthesis was progres-
sively deployed and the delivery system retrieved. Aortic
angiogram after deployment showed the correct positioning
of the prosthesis with a trivial paravalvular leak (Figure 1);
no transvalvular gradientwas detected. Finally, the 18F sheath
was removed and hemostasis of the right femoral artery was
successfully obtained by knotting the sutures of a preposi-
tioned suture-based closure device (Prostar XL 10F; Abbott
Vascular, Alameda, Calif). The in-hospital course was un-
eventful and the patient was discharged at home on day 6 after
the procedure.Dual antiplatelet treatment was prescribed for 6
months. At 6 months’ follow-up, the patient remained free of
adverse events, with persistent New York Heart Association
functional class I; a transthoracic echocardiogram confirmed
good performance of the implanted prosthesis with neither
aortic regurgitation nor significant transprosthetic gradient.
DISCUSSION
Recently, Wenaweser and associates2 reported the first
case of CoreValve implantation for the treatment of aortic
regurgitation in a degenerating bioprosthesis. They usedardiovascular Surgery c Volume 138, Number 4 1027
Brief Technique ReportsFIGURE 1. Aortic angiogram before (A) prosthesis implantation showing large aortic regurgitation; prosthesis positioning (B) and full deployment (C);
aortic angiogram after prosthesis implantation showing no further aortic regurgitation (D).general anesthesia with the hemodynamic support of a fem-
oro–femoral bypass with surgical cutdown of arteries. We
here reported, to the best of our knowledge, the first case
of PAVR to treat a severe aortic regurgitation in bioprosthe-
sis dysfunction. We used the third-generation CoreValve
device, avoiding surgical cutdown of femoral arteries and
the need for hemodynamic support. We thereby reduced
the potential complications related to multiple large sheath
placement and to hemodynamic pump use. In agreement
with previous reports, our case confirms the feasibility of
PAVR in aortic regurgitation caused by bioprosthesis dys-
function, with immediate hemodynamic improvement and
persistent clinical benefit. In light of these evidences, it could
be argued that stent-based valve implantation in degenerat-
ing prostheses may be more effective than in native valves;
the latter usually present a higher amount of calcification,
responsible for potential coronary ostial obstruction and
inadequate stent sealing to the aortic root with subsequent
residual paravalvular leak.3 We believe that PAVR with
a self-expandable prosthesis may represent in the future an1028 The Journal of Thoracic and Cardiovascular Sappropriate therapeutic alternative to surgical reintervention
in elderly patients affected by bioprosthesis dysfunction. In
fact, since the increase in life expectancy is leading to a huge
number of patients undergoing AVR at advanced ages, with
increasing use of bioprostheses, an expanding amount of
bioprosthesis dysfunction in elderly patients with multiple
comorbidities could be expected in the future. However,
data regarding long-term follow-up in a large number of
patients are needed to evaluate the real prognostic impact
of this treatment.
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